Leukotriene antagonists and corticosteroids suppress in vitro adenotonsillar proliferation in children with obstructive sleep apnea hypopnea syndrome

The Mechanism of Adenotonsillar Hypertrophy and Medication in Children with Obstructive Sleep Apnea Hypopnea Syndrome

Status

Recruiting

Phases

Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR-IIC-16008366

Enrollment

Unknown

Registered

2016-04-26

Start date

2013-02-01

Completion date

Unknown

Last updated

2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

obstructive sleep apnea hypopnea syndrome

Interventions

OSAHS-inhaled corticosteroids(ICS):use ICS before adenotonsillectomy

Eligibility

Sex/Gender

All

Age

2 Years to 14 Years

Inclusion criteria

Inclusion criteria: The children who is snoring and the polysomnorgraphy show that OAHI>1. Since adenotonsillar tissue cannot be obtained from normal children due to ethical reasons, patients with recurrent infectious tonsillitis (at least 5 tonsillar infections <6 months) but without snoring were selected as controls before surgery.

Exclusion criteria

Exclusion criteria: the presence of craniofacial, neuromuscular, cardiovascular, or genetic disordors; use of corticosteroids, antibiotics or leukotriene receptor antagonists(LTRAs) within 4 weeks; and previous AT.

Design outcomes

Primary

Measure	Time frame
cysteinyl leukotriene;leukotriene C4 synthase mRNA;cell proliferation rate;	—

Countries

China

Contacts

Public ContactAihuan Chen

State Key Laboratory of Respiratory Disease, The First Affiliated Hospital of Guangzhou Medical University

Chaih163@163.com+86 13501489828

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026